NRAS and melanoma: ROCK inhibitors also overcome targeted therapy resistance: Y-27632, GSK269962A, or fasudil restore BRAF inhibitor efficacy in melanoma, and ROCK1 silencing sensitizes BRAF/NRAS-mutant cells to MAPK inhibitors [72–74].